Doctors and researchers say it's too early to call it a cure but possibilities are looking good that Dostarlimab, animmunotherapy immunotherapy treatment, might be real deal. In clinical trials the drug had a 100% success rate - something that has never happened in the history of cancer research. Even better, patients remained cancer free 25 months after treatment. Lots more studies/trails need to be done but it's a super promising start. You can read a more in-depth write up about Dostarlimab here.
Photo: Getty Images